SEC Form 4 · accession 0001179110-18-011550

Blueprint Medicines Corp · BPMC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Sep 17, 2018

Accepted (ET)

Sep 19, 2018 · 4:08 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001597264

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 17, 2018	M	2,300	$37.11	A	2,300	D
Common Stock^F2	Sep 17, 2018	S	300	$73.05	D	2,000	D
Common Stock^F3	Sep 17, 2018	S	300	$70.59	D	1,700	D
Common Stock	Sep 17, 2018	S	1,700	$70.00	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$37.11	Sep 17, 2018	M	2,300	D	—	Nov 21, 2026	Common Stock	2,300	116,900	D

F1Effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.89 to $73.36 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.30 to $71.06 per share.
F4This option was granted on November 21, 2016. This option vested with respect to 25% of the shares underlying the option on November 21, 2017 and vests as to an additional 1/48th of the shares underlying the option each month thereafter.